-
公开(公告)号：KR1020120021239A
公开(公告)日：2012-03-08
申请号：KR1020110086459
申请日：2011-08-29
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/4704 , A61P35/00
CPC classification number: A61K31/4704
Abstract: PURPOSE: A composition containing rebamipide for preventing or treating cancer or immune diseases is provided to suppress Th17 cell differentiation and to enhance immune regulatory T cell activity. CONSTITUTION: A composition for preventing or treating cancer or immune diseases contains rebamipid compounds or pharmaceutically acceptable salt thereof as an active ingredient. The immune diseases include autoimmune disease, inflammatory disease, and transplantation rejection. A method for reducing or suppressing differentiation of immature T cells into Th17 cell in vitro comprises a step of treating rebamipid compounds or pharmaceutically acceptable salt thereof.
Abstract translation: 目的：提供含有用于预防或治疗癌症或免疫疾病的瑞巴派特的组合物以抑制Th17细胞分化并增强免疫调节性T细胞活性。 构成：用于预防或治疗癌症或免疫疾病的组合物含有雷米帕派化合物或其药学上可接受的盐作为活性成分。 免疫疾病包括自身免疫性疾病，炎性疾病和移植排斥反应。 用于在体外降低或抑制未成熟T细胞分化成Th17细胞的方法包括处理rebamipid化合物或其药学上可接受的盐的步骤。
-
公开(公告)号：KR1020110137588A
公开(公告)日：2011-12-23
申请号：KR1020100057601
申请日：2010-06-17
Applicant: 에이치 엘 지노믹스(주) , 가톨릭대학교 산학협력단
Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract and pharmaceutically acceptable carrier is provided to prevent and treat obesity. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity contains Vitis vinifera seed extract and pharmaceutically acceptable carrier. The extract has 80-130 of procyanidolic value(PCV) and contains less than 30% of (+)catechin and (-) epicatechin and 95-105% of proanthocyanidin content. A method for preparing the extract comprises: a step of mixing pulverized Vitis vinifera seed and a mixture solvent of acetone and water and isolating at room temperature; a step of filtering the extract and distilling the filtered liquid to remove acetone; a step of saturating sodium chloride and filtering; a step of extracting the liquid with ethyl acetate and concentrating; and a step of adding chloroform and filtering.
Abstract translation: 目的：提供含有葡萄籽提取物和药学上可接受的载体的药物组合物以预防和治疗肥胖症。 构成：用于预防或治疗肥胖症的药物组合物含有葡萄种子提取物和药学上可接受的载体。 提取物具有80-130原花青素值（PCV），并且含有少于30％的（+）儿茶素和（ - ）表儿茶素和95-105％的原花色素含量。 一种制备提取物的方法包括：将经粉碎的葡萄种子和丙酮和水的混合溶剂混合并在室温下分离的步骤; 过滤提取物并蒸馏过滤的液体以除去丙酮的步骤; 使氯化钠饱和并过滤的步骤; 用乙酸乙酯萃取液体并浓缩的步骤; 并加入氯仿和过滤步骤。
-
公开(公告)号：KR1020110125495A
公开(公告)日：2011-11-21
申请号：KR1020100045058
申请日：2010-05-13
Applicant: 가톨릭대학교 산학협력단
IPC: A61K48/00 , A61K31/7105 , C07K14/47
CPC classification number: A61K31/7105 , A61K48/005 , C07K14/4703 , A61K2121/00
Abstract: PURPOSE: A composition containing PIAS3 for preventing or treating cancer or immune diseases is provided to suppress the differentiation of cytotoxic Th17 cell. CONSTITUTION: A composition for preventing or treating cancer or immune diseases contains PIAS3 gene or protein of the gene as an active ingredient. PIAS3 reduces or suppresses the differentiation of undifferentiated T cells into Th17 cells. The immune diseases are autoimmune disease, inflammatory disease, or transplantation rejection. A composition for suppressing immunity contains the PIAS3 gene or protein thereof as an active ingredient.
Abstract translation: 目的：提供含有预防或治疗癌症或免疫疾病的PIAS3的组合物，以抑制细胞毒Th17细胞的分化。 构成：用于预防或治疗癌症或免疫疾病的组合物含有该基因的PIAS3基因或蛋白质作为活性成分。 PIAS3可降低或抑制未分化T细胞分化为Th17细胞。 免疫疾病是自身免疫性疾病，炎性疾病或移植排斥反应。 用于抑制免疫的组合物含有PIAS3基因或其蛋白质作为活性成分。
-
公开(公告)号：KR1020110121086A
公开(公告)日：2011-11-07
申请号：KR1020100040518
申请日：2010-04-30
Applicant: 가톨릭대학교 산학협력단
IPC: A01K67/027
CPC classification number: A01K67/027 , A01K2207/25 , A01K2227/105 , A01K2267/03
Abstract: PURPOSE: An arthritis mouse animal model and a manufacturing method thereof are provided to more seriously a symptom of arthritis. CONSTITUTION: A manufacturing method of an arthritis mouse animal model comprises: a step of inducing obesity by feeding high caloric fodder to mouse; and a step of causing arthritis by ministering collagen in the mouse. In the collagen ministering step, collagen is inoculated firstly, a mouse is bred for a specified period, and collagen is inoculated secondly. In the first inoculation, mixture solution of collagen and complete freud's adjuvant is administered. In the second inoculation, mixture solution of collagen and incomplete freud's adjuvant is administered.
Abstract translation: 目的：提供关节炎小鼠动物模型及其制造方法，以更严重地关注关节炎的症状。 构成：关节炎小鼠动物模型的制造方法包括：通过向小鼠喂食高热量饲料来诱导肥胖的步骤; 以及通过在小鼠中服用胶原来引起关节炎的步骤。 在胶原蛋白传代步骤中，首先接种胶原，将小鼠育种一段指定的时间，然后接种胶原蛋白。 在第一次接种中，施用胶原蛋白和完全弗氏佐剂的混合溶液。 在第二次接种中，施用胶原蛋白和不完全弗氏佐剂的混合溶液。
-
95.发明授权
公开(公告)号：KR101044433B1
公开(公告)日：2011-06-27
申请号：KR1020080087109
申请日：2008-09-04
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: 본 발명은 유럽종 포도(
Vitis
vinifera )의 씨 추출물의 개선된 제조방법을 제공한다. 또한, 본 발명은 유럽종 포도(
Vitis
vinifera )의 씨 추출물 및 약제학적으로 허용가능한 담체를 포함하는 류마티스 관절염의 예방 또는 치료용 약학 조성물을 제공한다.
유럽종 포도, 류마티스 관절염-
Patent Agency Ranking
公开(公告)号：KR1020110021016A
公开(公告)日：2011-03-04
申请号：KR1020090078547
申请日：2009-08-25
Applicant: 가톨릭대학교 산학협력단 , 한림제약(주)
IPC: A61K31/4704 , A61P19/02 , A61K9/20 , A61K9/48
CPC classification number: A61K31/4704
Abstract: PURPOSE: A pharmaceutical composition containing rabamipide and pharmaceutically acceptable carrier is provided to prevent or treat rheumatoid arthritis. CONSTITUTION: A pharmaceutical composition for preventing or treating rheumatoid arthritis contains rabamipid and pharmaceutically acceptable carrier. The pharmaceutical composition is used for oral administration. The pharmaceutical composition is formed in oral solid dosage. The pharmaceutical composition has rabamipid formulated in 0.5-50 mg/kg of unit dosage form.
Abstract translation: 目的：提供含有拉巴米特和药学上可接受的载体的药物组合物，以预防或治疗类风湿性关节炎。 构成：用于预防或治疗类风湿性关节炎的药物组合物含有拉帕米特和药学上可接受的载体。 药物组合物用于口服给药。 药物组合物以口服固体剂量形成。 药物组合物具有配制在0.5-50mg / kg单位剂型中的拉巴米特。
-
公开(公告)号：KR102256159B1
公开(公告)日：2021-05-26
申请号：KR1020140153669
申请日：2014-11-06
Applicant: 가톨릭대학교 산학협력단
Abstract: 본발명은 GKN 1을유효성분으로함유하는자가면역질환의예방또는치료용조성물에관한것으로, 보다구체적으로는 GKN 1 유전자를포함하는발현벡터또는 GKN 1 단백질을유효성분으로함유하는자가면역질환의예방또는치료용조성물에관한것이다. 본발명에따른 GKN 1은자가면역질환이발병한동물모델을대상으로상기단백질을과발현시킨경우자가면역질환의증상이개선되는것으로나타났고, 특히파골세포분화를효과적으로억제할수 있어골 관절염및 류마티스관절염을포함하는자가면역질환의치료제개발에유용하게사용할수 있는효과가있다.
-
公开(公告)号：KR102211959B1
公开(公告)日：2021-02-05
申请号：KR1020140107569
申请日：2014-08-19
Applicant: 가톨릭대학교 산학협력단
Abstract: 본발명은 DUSP5를유효성분으로모두포함하는골대사성질환의예방또는치료용약학적조성물, STAT3 매개질환의예방또는치료용약학적조성물및 DUSP5을이용한 STAT3의활성억제방법에관한것으로, 본발명은 DUSP5는파골세포분화와관련된 RANKL, RANK, NFATc1 및 TRAP의발현또는활성을효과적으로억제할수 있고, Th17의활성을억제또는감소시키고조절 T 세포(Regulatory T cell: Treg)의활성을촉진또는증가시키는작용이동시에가능하며, STAT3의인산화억제를통해 STAT3의활성을억제할수 있어, 골대사성질환및 STAT3 매개로인한질환을치료할수 있는새로운치료제로서유용하게활용가능할것이다.
-
99.发明公开메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물 有权含有二甲双胍的组合物，用于减少由免疫抑制药物引起的肾毒性并用于预防或治疗免疫疾病
公开(公告)号：KR20180036688A
公开(公告)日：2018-04-09
申请号：KR20180038355
申请日：2018-04-02
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/155 , A61K9/16 , A61K9/20 , A61K31/436 , A61K38/13 , A61K47/36
CPC classification number: A61K31/155 , A61K31/436 , A61K38/13
Abstract: 본발명은메트포민(metformin)을포함하는면역억제제로인한신장독성완화용조성물및 이를포함하는면역질환예방또는치료용조성물에관한것으로, 보다상세하게는메트포민을유효성분으로포함하는면역억제제로유발된신장독성감소용조성물, 메트포민과칼시뉴린억제제(calcineurin inhibitor)를유효성분으로포함하는면역질환의예방또는치료용약학적조성물및 메트포민과칼시뉴린억제제를구성요소로포함하며이들을동시에, 개별적으로또는정해진순서로투여하는것을특징으로하는면역질환의예방또는치료용약학적복합제제에관한것이다. 본발명의조성물은기존면역억제제의부작용으로생기는신장기능저하를효과적으로완화하여면역억제가필요한질병의치료효과를높이는데유용하게이용될수 있으며, 더나아가기존의면역억제제와메트포민을병용투여하는다양한방법을제시하여기존면역억제제의신장독성부작용은줄이고, 면역억제또는면역조절효과는극대화함으로써, 장기이식거부반응, 자가면역질환, 염증성질환등을예방하거나치료하는데유용하게이용될수 있다.
Abstract translation: 本发明提供用于缓解由免疫抑制药引起的肾毒性的组合物，包含二甲双胍，以及用于预防或治疗免疫疾病的组合物及其组合物。 此外，所提供的组合物可以是在改善由有效缓解肾功能的下降，需要免疫抑制的疾病的治疗效果有用起因于侧常规免疫抑制药物的效果，并且也可以是在预防或治疗器官移植排斥，自身免疫疾病是有用 病，炎性疾病和自共同给予常规免疫抑制药物和二甲双胍的各种方法等建议，以减少常规的免疫抑制药物的肾毒性的副作用和免疫抑制最大化或免疫调节作用。
-
公开(公告)号：KR101828606B1
公开(公告)日：2018-02-14
申请号：KR1020110047180
申请日：2011-05-19
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/203 , A61K9/127 , A61P29/00 , A61P37/00
Abstract: 본발명은레티노산(retinoic acid)을활성성분으로함유하는나노좀형태의면역치료제에관한것이다. 본발명의레티노산을활성성분으로포함하는나노좀형태의면역치료제는불안정한레티노산을안정하게포함할뿐만아니라, 표적부위로의레티노산전달율이높기때문에, 레티노산자체를직접적으로사용한경우와비교하여염증성사이토카인인 TNF-α와 IL-17의생성을더욱효과적으로억제시킬수 있으므로, 면역질환예방또는치료에서유용하게사용될수 있다.
Abstract translation: 本发明涉及含有视黄酸作为活性成分的纳米形式免疫治疗剂。 由于含有视黄酸作为本发明的有效成分的免疫治疗剂的纳米位形式不仅包括稳定 - 不稳定视黄酸，目标部位的高视黄酸递送速率，以直接与视黄酸本身的情况相比， 可以更有效地抑制炎性细胞因子TNF-α和IL-17的产生，因此可以有效用于预防或治疗免疫疾病。
-
-
-
-
-
-
-
-
-
Search Results
262
records
(took 0.029 seconds)
